Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.52 |
| ▸ | PAK4 | O96013 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | LTK | P29376 | 1/20 | 0.52 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.52 |
| ▸ | PRKX | P51817 | 1/20 | 0.52 |
| ▸ | NEK2 | P51955 | 1/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.52 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.52 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2053008 | 0.88 | AMY1A (0.41) | CBFBCHEK1PRKD3PAK4PDGFRA | |
| SCHEMBL8190402 | 0.81 | ESR1 (0.62) | PLAUAMY1AF2F10PLG | |
| SCHEMBL2048080 | 0.78 | NPC1 (0.64) | AURKBGAAPKMTSHRNPC1 | |
| SCHEMBL21976219 | 0.78 | CYP2A6 (0.44) | CBFBGAAF2F10NPBWR1 | |
| SCHEMBL20088846 | 0.76 | HDAC6 (0.64) | — | |
| SCHEMBL1803420 | 0.76 | ESR1 (0.70) | PKMESR1KDM4EMEN1ALDH1A1 | |
| SCHEMBL21018195 | 0.76 | CHEK1 (0.81) | CBFBCHEK1PRKD3PAK4PDGFRA | |
| Bromide SCHEMBL3194129 | 0.74 | ALDH1A1 (0.49) | GAADGAT1NPC1KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL3203756 | 0.74 | ALDH1A1 (0.49) | GAADGAT1NPC1KDM4EMEN1 | |
| SCHEMBL3195220 | 0.72 | SMN1; SMN2 (0.45) | RPS6KA3AURKBGAAPKMNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727808-B3 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LTD (GB) | 2013-01-09 | — | — | EP | disclosed |
| US-20110160192-A1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| EP-1727808-B1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | SPIROGEN LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| EP-1727808-A2 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | Spirogen Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005085177-A2 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160192-A1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | PCNA, POLL, XPA | CBFB 51/4885CHEK1 718/4885PRKD3 3296/4885 |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | PCNA, POLL, DNA2 | CBFB 48/4885CHEK1 686/4885PRKD3 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.